Veracyte (VCYT) Change in Accured Expenses (2012 - 2026)

Veracyte has disclosed Change in Accured Expenses across 15 years of filings, most recently posting -$6.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$6.1 million, up 31.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (up 149.25% YoY), and the FY2025 annual result was $6.3 million, up 78.37% from the prior year.
• Change in Accured Expenses came in at -$6.1 million for Q1 2026 at Veracyte, down from -$718000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.9 million in Q2 2024 to a low of -$9.0 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is -$351000.0 (2024), against an average of -$50529.4.
• Across the five-year window, Change in Accured Expenses sank 1879.74% in 2023 and soared 45525.0% in 2025, its largest moves.
• Veracyte's Change in Accured Expenses stood at $2.1 million in 2022, then climbed by 29.34% to $2.7 million in 2023, then plunged by 112.89% to -$351000.0 in 2024, then tumbled by 104.56% to -$718000.0 in 2025, then tumbled by 752.37% to -$6.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.1 million (Q1 2026), -$718000.0 (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.